Search for: "Teva USA"
Results 221 - 240
of 713
Sort by Relevance
|
Sort by Date
24 Sep 2017, 5:04 pm
Teva Pharmaceuticals USA, Inc. [read post]
23 Sep 2017, 12:39 pm
USA, Inc. v. [read post]
29 Aug 2017, 7:35 am
Teva Pharmaceuticals USA, Inc. et al, 2-15-cv-01455 (TXED August 25, 2017, Order) (Bryson, CJ) [read post]
17 Aug 2017, 7:49 am
USA, Inc. v. [read post]
20 Jul 2017, 12:47 pm
On July 7, 2017, Teva Pharmaceuticals USA, Inc. filed a complaint in the Eastern District of Pennsylvania alleging that a former executive disclosed confidential information to a romantic partner who happens to be an executive of one of Teva’s direct competitors. [read post]
20 Jul 2017, 12:47 pm
On July 7, 2017, Teva Pharmaceuticals USA, Inc. filed a complaint in the Eastern District of Pennsylvania alleging that a former executive disclosed confidential information to a romantic partner who happens to be an executive of one of Teva’s direct competitors. [read post]
17 Jul 2017, 9:41 am
Teva Pharm. [read post]
26 Jun 2017, 7:51 am
Teva Pharmaceuticals USA, Inc., the Federal Circuit panel of Judges Dyk, Mayer and O’Malley determined: “after the AIA, if the existence of the sale is public, the details of the invention need not be publicly disclosed in the terms of sale” for the sale to be invalidating. [read post]
25 Jun 2017, 9:25 pm
., USA and Teva Pharmaceuticals USA, Inc. to a Report and Recommendation issued by Magistrate Judge Burke and adopted the Report. [read post]
13 Jun 2017, 12:00 pm
Teva Pharmaceuticals USA, Inc., the Federal Circuit had its first opportunity to address the impact of the “or otherwise available to the public” clause contained in post-AIA 35 U.S.C. [read post]
13 Jun 2017, 12:00 pm
Teva Pharmaceuticals USA, Inc., the Federal Circuit had its first opportunity to address the impact of the “or otherwise available to the public” clause contained in post-AIA 35 U.S.C. [read post]
12 Jun 2017, 5:40 pm
USA, Inc. v. [read post]
8 Jun 2017, 3:27 am
Teva Pharmaceuticals USA, Inc., the Federal Circuit had its first opportunity to address the impact of the “or otherwise available to the public” clause contained in post-AIA 35 U.S.C. [read post]
28 May 2017, 8:19 pm
Biosig Instruments, Inc. and Teva Pharmaceuticals USA, Inc. v. [read post]
25 May 2017, 6:20 pm
A post concerning future generic "Copaxone" at raps.org beginsGeneric versions of Teva's multi-billion-dollar per year multiple sclerosis drug Copaxone (glatiramer) are coming, but a closer look at which competitor might win the coveted 180-day exclusivity for its generic reveals an unusual and complex situation.Back in January, a US District Court for the District of Delaware ruling invalidated all asserted claims on Teva's patents on its 40mg version of… [read post]
11 May 2017, 8:48 am
USA, Inc. v. [read post]
9 May 2017, 9:49 am
By Dennis Crouch Nestle USA v. [read post]
7 May 2017, 3:30 am
Teva Pharms. [read post]
4 May 2017, 8:26 am
(“Helsinn”) brought suit against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. [read post]
4 May 2017, 8:26 am
(“Helsinn”) brought suit against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. [read post]
